The confidential portions of this exhibit have been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN ***. AMENDMENT NO. 2 TO LICENSE AND SUPPLY AGREEMENT

This Amendment No. 2 to License and Supply Agreement (this “Amendment”) is entered into with effect as of December 31, 2012 (“Amendment Effective Date”), by and among Endo Pharmaceuticals Inc., a Delaware corporation having a principal place of business at 100 Endo Drive, Chadds Ford, Pennsylvania 19317 (“Endo”), Novartis Consumer Health, Inc., a Delaware corporation having a principal place of business at 200 Kimball Drive, Parsippany, New Jersey 07054 (“Novartis”), and Novartis AG, a Swiss corporation having a principal place of business in Basel, Switzerland (“Novartis AG”). Each of Novartis AG, Novartis and Endo is referred to herein individually as a “Party” and collectively as the “Parties.”

WHEREAS, the Parties entered into a License and Supply Agreement, dated March 4, 2008, which was amended by that certain Amendment No. 1 to License and Supply Agreement, dated March 28, 2008 (as amended, the “License and Supply Agreement”);

WHEREAS, the Parties desire to amend the License and Supply Agreement as provided herein;

WHEREAS, the terms and conditions in the License and Supply Agreement continue to be in full force and effect between the Parties except as modified as set forth below;

NOW THEREFORE, in consideration of the premises and covenants herein contained the Parties agree as follows:

2.    Amendment to Section 4.4(b). The table in Section 4.4(b) of the License and Supply Agreement shall be amended and restated to read as follows:

3.    Amendment to Section 4.9. The table in Section 4.9 of the License and Supply Agreement shall be amended and restated to read as set forth below. The following sentence shall be added to the end of Section 4.9 of the License and Supply Agreement: “Notwithstanding anything herein to the contrary, in Agreement

Year 5 and each Renewal Term thereafter until NOVARTIS notifies ENDO in writing of its ***, ENDO’s annual minimum expenditures of A&P Expenses as set forth in Column 5 of the table in this Section 4.9 shall be reduced by *** percent (***%) from the levels set forth in Column 5.”

4.    Amendment to Section 5.9(b). The following sentence shall be added to the end of Section 5.9(b)(i) of the License and Supply Agreement:

“Notwithstanding anything herein to the contrary, effective January 1, 2013, the price for Licensed Product shall be reduced by *** percent (***%), which shall translate into a reduction of $***/unit for the 100g tube (currently priced at $***/unit) and a reduction of $***/unit on the 20g tube (currently priced at $***/unit); it being understood that this price reduction shall remain in effect throughout the Term of this Agreement. In the event of any future price increases, the foregoing amounts ($***/unit for 100g tube and $***/unit for 20g tube) shall be deducted from the total price otherwise permitted to be charged under the current License and Supply Agreement.”

5.    Amendment to Section 9.1. The last three sentences of Section 9.1 of the License and Supply Agreement are hereby amended and restated to read as follows:

“ENDO shall cooperate fully with NOVARTIS in connection with an OTC Switch, including, providing any materials reasonably required by NOVARTIS to support the OTC Switch. Notwithstanding the foregoing, NOVARTIS shall not Launch an OTC Equivalent Product prior to April 1, 2014, and NOVARTIS shall not take any action that results in the loss of Rx Product status for the Licensed Product prior to such time. NOVARTIS shall notify ENDO when it submits a filing to the FDA in respect of an OTC Equivalent Product.”

6.    Amendment to Section 17.1(a). The following clause shall be added to the end of the last sentence in Section 17.1(a) of the License and Supply Agreement: “; provided that notwithstanding the foregoing, in no event shall the NOVARTIS Parties provide notice of non-renewal prior to January 1, 2016.” For the avoidance of doubt, nothing in this Amendment shall amend or restate, or be deemed to amend or restate, any provision of Section 17.2 or Section 17.3 of the License and Supply Agreement or limit the rights of a NOVARTIS Party to terminate the License and Supply Agreement pursuant to Section 17.2 or Section 17.3 of the License and Supply Agreement.

7.    Conflict. This Amendment will govern if it conflicts with any provision of the License and Supply Agreement. 

8.    Effectiveness of the Agreement. The Parties acknowledge and agree that this Amendment constitutes a valid and binding amendment to the License and Supply Agreement for purposes of Section 20.6 of the License and Supply Agreement. For the avoidance of doubt, nothing in this Amendment shall be deemed to amend, modify, delete or extend the disclaimers of warranties in Section 13.4 of the License and Supply Agreement or limitations of damages in Section 20.16 of the License and Supple Agreement, which disclaimers and limitations shall apply to this Amendment as if set forth in full herein. This Amendment may be executed in several counterparts, each of which shall be deemed an original and all of which taken together shall constitute a single instrument. Except as set forth in this Amendment, there are no other amendments to the License and Supply Agreement and the License and Supply Agreement remains in full force and effect as amended as of the Amendment Effective Date.

IN WITNESS WHEREOF, this Amendment No. 2 to License and Supply Agreement has been executed by the authorized officers of the Parties hereto with effect as of the Amendment Effective Date.